{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dementia/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"60bd6b27-027f-56a6-a018-a1d694a6a2f3","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 4b37f2cb-06d4-4336-9bfe-e557fea5a37b --><h2>Changes</h2><!-- end field 4b37f2cb-06d4-4336-9bfe-e557fea5a37b -->","summary":null,"htmlStringContent":"<!-- begin item bd82b887-1919-4d71-a40f-e17e9e0dfa58 --><!-- begin field 267ec830-a8f1-4912-a591-cb109e3d50dc --><p><strong>October 2020 </strong>— minor update. Information that the death of anyone subject to Deprivation of Liberty Safeguards (DoLS) must be reported to the coroner has been removed as this is no longer a requirement. </p><p><strong>August 2020 </strong>— minor update. NICE Quality standards updated with QS194.</p><p><strong>June 2020 </strong>— minor update. Information on the cognitive assessment tools recommended by NICE have been updated in line with the NICE guideline <em>Dementia: assessment, management and support for people living with dementia and their carers</em>.</p><p><strong>July 2019</strong> — minor update. NICE Quality standards updated with QS184 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2019</a>]. </p><p><strong>May 2017</strong> — minor update. A typographical error was corrected.</p><p><strong>December 2016</strong> — minor update. A typographical error was corrected.</p><p><strong>August 2016</strong> — reviewed. A literature search was conducted in June 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last review of this topic. No major changes to recommendations have been made, but the topic has undergone minor restructuring.</p><!-- end field 267ec830-a8f1-4912-a591-cb109e3d50dc --><!-- end item bd82b887-1919-4d71-a40f-e17e9e0dfa58 -->","topic":{"id":"de9cbb4d-2d69-500f-be27-dc83f76dc3ba","topicId":"2491e3e7-cc21-42b9-8972-e54804b4782f","topicName":"Dementia","slug":"dementia","lastRevised":"Last revised in October 2020","chapters":[{"id":"af834011-0042-530a-8f9a-acd5828e0a34","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0360b83-4555-5079-897f-12b2d555c1af","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"52cd8e36-39cd-5259-8819-bd96087b0265","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"60bd6b27-027f-56a6-a018-a1d694a6a2f3","slug":"changes","fullItemName":"Changes"},{"id":"7ced1224-30c2-5f30-9caf-3764f3665ae4","slug":"update","fullItemName":"Update"}]},{"id":"fae05cff-ad98-52fa-89b4-b97369195d59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2f3b4bd3-e7cf-5492-afe0-0a5b230eab7e","slug":"goals","fullItemName":"Goals"},{"id":"9104785e-e491-5ca3-b3d3-7e951385bce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a9c56eb4-bc0e-51cc-b486-a54c23906bc0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ebf62eba-a4cd-536c-8c9f-c9505b0e7482","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a71b8dc2-79f8-5d24-b668-c792abc5a624","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c87232ba-6926-5ff2-98d2-f8839b0c0d37","slug":"nice-quality-standards","fullItemName":"NICE Quality Standards"}]},{"id":"825c29c3-9d55-54ae-b54d-8ee2ac796e97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"46c6316f-eec0-580a-80ec-2112d2f0122f","slug":"definition","fullItemName":"Definition"},{"id":"f485482d-0d4e-52cb-9df4-3548bc72a566","slug":"causes","fullItemName":"Causes"},{"id":"87101d89-6073-57cc-b247-48be586ef185","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"58f6ec5a-c90b-5e64-a476-fc9fca39c6ae","slug":"prevalence","fullItemName":"Prevalence"},{"id":"994469e3-f824-5f48-b755-7f74dd360680","slug":"prognosis","fullItemName":"Prognosis"},{"id":"718f9ed4-d725-5f6e-a86f-5df88719cd52","slug":"complications","fullItemName":"Complications"}]},{"id":"366bcbe3-827a-5e08-9d81-8de84e46fefd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"565bac2a-ada3-5b0a-ab7d-6681501b2c4a","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"4c0fe55f-40c9-5a1c-8cf3-1ec8d88406d5","slug":"assessment","fullItemName":"Assessment"},{"id":"ef7780bd-8e94-5f95-870f-92ab930c4365","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3069f5e5-519f-50ec-81b7-c8948a5b3117","fullItemName":"Management","slug":"management","subChapters":[{"id":"c6c0cbc2-18fc-5bf8-973d-bc38b9001f28","slug":"suspected-dementia","fullItemName":"Scenario: Suspected dementia"},{"id":"6320a2da-e9d6-5f57-94d9-0433261edf89","slug":"follow-up-of-confirmed-dementia-in-primary-care","fullItemName":"Scenario: Follow up of confirmed dementia in primary care"},{"id":"343a59fa-439e-5ab9-9d3b-28a893d55d2f","slug":"management-of-end-stage-dementia","fullItemName":"Scenario: Management of end-stage dementia"}]},{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"58ed8441-e3ca-566e-9afb-92a5ba60b1dd","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"67092bd7-2ab4-5e8b-8ead-5301454da4a8","slug":"acetylcholinesterase-inhibitors","fullItemName":"Acetylcholinesterase inhibitors"},{"id":"f4ced652-a6de-5e19-ae37-6de43dfd8104","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"45d5f01b-c1c2-53dc-91b4-8f7a90983fd5","slug":"memantine-hydrochloride","fullItemName":"Memantine hydrochloride"}]},{"id":"1e87c908-2ab5-5cba-8d6a-958c03f7a6cd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fc7a2bcf-854b-5ca4-9b02-2dcaaebe1162","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7bcb26a3-cc69-5201-9fd9-6353e27b412f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c383917-58d0-5036-8217-5d9fd81cb2cb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fdb8af52-aeee-52bd-be79-c5534939d42f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a9f930f3-f8b6-5c8f-b8ca-b3155e0c23d3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"668c11fa-1873-58d4-b0e2-3eab90e8fbff","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67c4aef9-fbf4-5bf6-8dc5-c501f74b1fe3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"52cd8e36-39cd-5259-8819-bd96087b0265","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"a60a3628-3f7c-5f04-a739-1bb05f5fb436","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field d9c09f0b-0745-4156-9dea-a619c004bfbe --><h3>Previous changes</h3><!-- end field d9c09f0b-0745-4156-9dea-a619c004bfbe -->","summary":null,"htmlStringContent":"<!-- begin item 26c1a0f0-bd8c-437e-92c8-986e244f3994 --><!-- begin field 35bb92f5-94d7-426a-bd32-2586f4a0ff6b --><p><strong>June 2015</strong> — minor update. Based on an update in 2015 to the manufacturer's Summary of Product Characteristics (SPC), decreased appetite has been included as a common adverse effect of rivastigmine.</p><p><strong>April 2015</strong> — minor update. Update to the text to reflect new advice from the Department of Transport on drugs and impaired driving.</p><p><strong>August 2014 </strong>— minor update to include Prometax® rivastigmine patches.</p><p><strong>July 2014 </strong>— two minor updates:</p><ul><li>Minor update to the text to reflect the fact that donepezil is now available as an oral liquid.</li><li>The text has been updated to replace the Liverpool Care Pathway with new standards of care that have been issued by the Leadership Alliance for the Care of Dying People (<a href=\"http://www.nhsiq.nhs.uk/\" style=\"background-color: rgb(255, 255, 255);\" data-hyperlink-id=\"09fb2af8-83e4-46d3-ac4d-a8f7014b1557\">www.nhsiq.nhs.uk</a>).</li></ul><p><strong>June 2014 </strong> — minor update. Update to the text to include the Alzheimer's Research UK as a source of information for people with dementia.</p><p><strong>February 2014 </strong> — minor update. Neuroleptic malignant syndrome has been added as a rare adverse effect of donepezil, following an update of the manufacturer's SPC.</p><p><strong>July 2013 </strong> — minor update. Links to the Driver and Vehicle Licensing Agency (DVLA) website have been updated.</p><p><strong>June 2013 </strong> — minor update. The 2013 Quality and Outcomes Framework (QOF) options for local implementation have been added to this topic.</p><p><strong>May 2013</strong>  — minor update. Following further comments from the April 2013 enquirer, the doses for both lorazepam and haloperidol have been further revised to read: </p><ul><li>Oral lorazepam — prescribe a starting dose of 0.5 mg daily. If necessary, the dose can be gradually increased to a maximum of 1 mg daily (2 mg daily in exceptional circumstances) in divided doses. </li><li>Oral haloperidol — prescribe a starting dose of 0.5 mg daily. If necessary, the dose can be gradually increased to a maximum of 2 mg daily (4 mg daily in exceptional circumstances) in divided doses. The basis for recommendation, prescribing information, and prescriptions have also been amended.</li></ul><p><strong>April 2013</strong> — minor update. Following an enquiry regarding the treatment of behavioural problems in dementia, the recommended maximum daily dose of lorazepam has been reduced from 4mg to 2 mg to be in line with the British National Formulary (BNF) and the manufacturers, who recommend half the adult dose in the elderly. We have also reworded the recommendation to make it clearer that treatment should be started with a low dose and gradually titrated upwards.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>January 2013</strong> — minor update. Removed the black triangle status from risperidone as this is no longer a black triangle drug.</p><p><strong>October 2012</strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>January 2012 </strong>— minor update. Prescribing information has been added for memantine, and the Basis for recommendation section has been updated to reflect the most recent considerations of the National Institute for Health and Care Excellence (NICE) regarding memantine. Issued in January 2012.</p><p><strong>October 2011 </strong>— minor update. A brief summary of the key recommendations from the World Alzheimer Report 2011 that emphasizes the benefits of early diagnosis and intervention, has been included in the background information section. Issued in November 2011.</p><p><strong>May 2011</strong>— minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>April 2011</strong> — minor update. Text added to reflect new recommendations from NICE regarding acetylcholinesterase inhibitors and memantine: <em>Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease</em>. Issued in June 2011.</p><p><strong>July 2010 </strong>— minor update. The NICE quality standard relating to dementia have been added to the section on Goals and outcome measures. Issued in August 2010.</p><p><strong>November 2009 to March 2010 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 35bb92f5-94d7-426a-bd32-2586f4a0ff6b --><!-- end item 26c1a0f0-bd8c-437e-92c8-986e244f3994 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}